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https://doi.org/10.1016/j.ccell.2019.08.008SUMMARYLoss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy resistance. A
genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved function of polycomb repressive
complex 2 (PRC2) that mediates coordinated transcriptional silencing of the MHC-I antigen processing
pathway (MHC-I APP), promoting evasion of T cell-mediated immunity. MHC-I APP gene promoters in
MHC-I low cancers harbor bivalent activating H3K4me3 and repressive H3K27me3 histone modifications,
silencing basal MHC-I expression and restricting cytokine-induced upregulation. Bivalent chromatin at
MHC-I APP genes is a normal developmental process active in embryonic stem cells and maintained during
neural progenitor differentiation. This physiological MHC-I silencing highlights a conserved mechanism by
which cancers arising from these primitive tissues exploit PRC2 activity to enable immune evasion.INTRODUCTION
Cancer immune surveillance requires co-operation of innate and
adaptive immune systems to eradicate developing tumors. The
key effectors of tumor elimination are CD8+ cytotoxic T cells thatSignificance
Here we show that cancer cells co-opt an evolutionarily conse
antigen processing and presentation pathway and evade imm
MHC-I APP genes is reversible following pharmacological inhib
of effective T cell-mediated anti-tumor immunity and providin
therapy to treat these aggressive MHC-I-deficient malignanci
therapies may occur not only through genomic mutations tha
mechanisms that exploit the activity of repressive chromatin c
Cancer Cell 36, 385–401, Oc
This is an open access article undrecognize and kill cells displaying foreign antigens bound to
MHC class I (MHC-I) molecules (Gubin et al., 2014; Tumeh et al.,
2014). Viruses have evolved a multitude of mechanisms to
decreaseMHC-I expression in infectedcells toevadeTcell surveil-
lance and, similarly, reduced expression of MHC-I in cancer cellsrved, lineage-specific function of PRC2 to silence the MHC-I
une surveillance. Importantly, PRC2 mediated silencing of
ition of EED or EZH2 and EZH1, leading to re-establishment
g a rationale for combining PRC2 inhibitors with immuno-
es. Our findings suggest that resistance to cancer immuno-
t inactivate the MHC-I APP but also through non-genomic
omplexes such as PRC2.
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Figure 1. A Whole Genome CRISPR Screen Identifies a Critical Role for PRC2 in Silencing MHC-I Expression in Cancer Cells
(A) CRISPR screen. K-562 cells were mutagenized by infection with a pooled lentiviral library comprising 220,000 sgRNA and MHC-I high cells were enriched by
three successive sorts using fluorescence-activated cell sorting.
(B) Cell surface MHC-I in K-562 cells following incubation ± IFN-g 10 ng/mL for 24 h.
(C) Bubble plots show the top 1,000 enriched genes identified in the CRISPR screen. PRC2 genes indicated in red. p values calculated using the RSA algorithm
(Konig et al., 2007).
(legend continued on next page)
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provides a mechanism of resistance to CD8+ T cell-mediated im-
mune attack. Recent major breakthroughs in cancer immuno-
therapy, particularly the capacity of antibodies targeting the
T cell inhibitory receptors PD-1 and CTLA-4 to induce sustained
disease remission in a proportion of cancer patients, has renewed
interest in themolecular understanding of tumor antigen presenta-
tion. Consistent with a central role for cytotoxic T cells as the key
effector cell activated in immune checkpoint inhibitor (ICI)-treated
patients, mutations in genes encoding components of the MHC-I
antigen processing pathway (APP) or the interferon-g (IFN-g)
response pathway have emerged as a frequent cause of both pri-
mary and acquired resistance (Manguso et al., 2017; Zaretsky
etal., 2016;Shinetal., 2017;Gaoetal., 2016;Panetal., 2018;Patel
et al., 2017; Kearney et al., 2018). Conversely, augmenting the
IFN-g response and MHC-I expression enhances T cell-mediated
anti-tumor immunity (Patel et al., 2017; Pan et al., 2018; Manguso
et al., 2017). Together these studies emphasize the central
importance of understanding the regulation of MHC-I antigen
presentation in cancer cells to enable effective targeting with
immunotherapy.
Transcriptional repression of MHC-I has been observed in a
range of cancers, including neuroendocrine tumors such as
N-myc-driven neuroblastoma, small-cell lung cancer (SCLC)
and Merkel cell carcinoma (MCC), and has recently been identi-
fied as a mechanism of resistance to immunotherapy (Bernards
et al., 1986; Restifo et al., 1993; Paulson et al., 2018). While
MHC-I is universally expressed on normal nucleated cells, the
quantitative expression of individual HLA genes is regulated in
tissue- and cell-type-specific patterns to modulate immune
function (Rene et al., 2016). During fetal development, selective
transcriptional downregulation of HLA-A and HLA-B in the fetal
extravillous trophoblast facilitates maternal tolerance of pater-
nally encoded MHC-I alleles (Tilburgs and Strominger, 2013).
Downregulation of MHC-I genes has also been observed in adult
quiescent tissue-specific stem cells in the hair follicle andmuscle
(Agudo et al., 2018). These observations imply the existence of
conserved physiological epigenetic regulatory mechanisms to
suppress MHC-I expression that could provide a survival advan-
tage to cancer cells under immune selection pressure. In
contrast to mutations in MHC-I APP genes, transcriptional
downregulation of MHC-I is potentially reversible and thus
amenable to pharmacological manipulation. Here we aim to
identify and characterize the molecular mechanisms underpin-
ning MHC-I silencing in MHC-I low cancers.
RESULTS
A Whole Genome CRISPR/Cas9 Screen Identifies an
Essential Role for Polycomb Repressive Complex 2 in
Maintaining Transcriptional Repression of MHC-I
To identify conserved negative regulators of MHC-I expres-
sion, we performed a positive selection flow cytometry-based
whole genome CRISPR/Cas9 screen in K-562 cells (Figure 1A),(D and E) EED KO K-562 cells were transduced with a lentiviral vector encoding
immunoblot (E).
(F) mRNA expression (reads per kilobase of transcript per million mapped reads)
Each dot represents an individual cancer cell line, clustered by tumor type (log2
See also Figure S1 and Table S1.a well-characterized erythroleukemia line that lacks cell sur-
face expression of all classical HLA alleles in the absence of
IFN-g stimulation (Figure 1B). Supporting a key role for epige-
netic regulation of MHC-I expression in cancer cells, all the
top candidate genes identified from cells with reactivated
MHC-I detected with either an HLA-B-specific or a pan-
HLA-A/B/C antibody encoded epigenetic regulators (Figures
1C and S1A; Table S1). Several of the targets are known to
function together in multicomponent complexes, supporting
the validity of these hits. The most significantly enriched of
these were single guide RNAs (sgRNAs) targeting EED and
SUZ12, encoding core components of polycomb repressive
complex 2 (PRC2). MTF2, encoding a facultative subunit of
PRC2.1 subcomplexes that has been implicated in PRC2
recruitment, was also among the top hits (Figure 1C; Table
S1). PRC2 is a well-known epigenetic repressive complex
that has a critical role in modulating gene expression during
embryonic development, therefore this complex was priori-
tized for validation. Depletion of EED using independent
sgRNAs restored MHC-I to the cell surface of K-562 cells (Fig-
ures 1D, S1B, and S1C), while established EED and EZH2
knockout (KO) cells maintained MHC-I expression without
substantial impairment in cell proliferation (Figure S1D).
Importantly, reconstituting PRC2 function by expression of
EED cDNA in EED KO cells was sufficient to restore
H3K27me3 levels and reinstate silencing of actively tran-
scribed MHC-I genes (Figures 1D and 1E). These findings
demonstrate a critical role for PRC2 in both establishing and
maintaining transcriptional repression of MHC-I genes.
Among all tumor types represented in the Cancer Cell Line
Encyclopedia (Barretina et al., 2012), SCLC and neuroblastoma
exhibit the lowest expression of multiple MHC-I APP genes,
implying broad repression of the MHC-I APP in these neuroen-
docrine tumors (Figures 1F and S1E) (Restifo et al., 1993;
Bernards et al., 1986). Notably, high expression of EZH2, the
catalytic component of PRC2, is a typical feature of both SCLC
and neuroblastoma (Figures S1F and S1G), and has been impli-
cated in pathogenesis and therapy resistance (Gardner et al.,
2017; Chen et al., 2018).
Supporting a conserved function for PRC2 in MHC-I silencing,
EED KO restored cell surface expression of MHC-I in human
SCLC and neuroblastoma cells (Figures S2A and S2B). Tri-
methylation of histone H3 on lysine 27 (H3K27me3), the hallmark
of genes repressed by PRC2, is catalyzed by the lysine
methyltransferase EZH2. Several potent and highly selective
S-adenosyl-methionine (SAM)-competitive inhibitors of EZH2
methyltransferase activity have been developed and are in clin-
ical trials in a range of malignancies. Treatment with these inhib-
itors substantially depleted H3K27me3 levels concomitant with
transcriptional induction of MHC-I genes (Figures 2A and 2B).
Importantly, pharmacological inhibition of EZH2 restored cell
surface MHC-I in K-562 and cell lines representative of neuro-
blastoma, SCLC, and MCC, a neuroendocrine cancer recentlyeither EED cDNA or GFP (vector, V) and analyzed by flow cytometry (D) and
of MHC-I genes in 920 cancer cell lines in the Cancer Cell Line Encyclopedia.
scale, black line indicates median).
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Figure 2. PRC2 Maintains Coordinated Silencing of Antigen Processing Genes in MHC-I-Deficient Cancers
(A and B) K-562 cells incubated with 3 mM EPZ-011989 (EZH2i) for the indicated times were analyzed by immunoblot (A) and qRT-PCR (B).
(C) Cell surface MHC-I in EZH2i-treated cells (GSK-503 5 mM in NCI-H146 and EPZ-011989 3 mM in Kelly, MCC-002, and K-562) after 10 days of treatment.
(legend continued on next page)
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shown to escape from immunotherapy through transcriptional
downregulation ofMHC-I genes (Figure 2C) (Paulson et al., 2018).
The enzymatic function of EZH2 is markedly potentiated by the
WD40 repeats of EED, which form an aromatic cage that binds to
H3K27me3 to allosterically activate EZH2 and perpetuate
H3K27me3 deposition (Margueron et al., 2009; Ueda et al.,
2012). Genetic disruption of the EED aromatic cage impaired the
ability of PRC2 to reinstate transcriptional repression of MHC-I,
arguing that H3K27 is the critical target of EZH2methyltransferase
activity for this process (Figures 2D and S2C). To test this more
directly, we took advantage of an H3 variant oncohistone with a
lysine-27 to methionine mutation (H3.3 K27M), which is a major
driver of pediatric diffuse intrinsic pontine glioma and acts in a
dominant negative manner to inhibit allosteric activation of PRC2
and spreading of the H3K27me3 repressive mark (Stafford et al.,
2018; Harutyunyan et al., 2019). Expression of H3.3 K27M in
K-562 cells potently induced MHC-I expression (Figures 2E and
2F), demonstrating a pivotal role for the establishment of
H3K27me3 repressive chromatin domains to maintain MHC-I
silencing. In keeping with this, mutation of a critical catalytic
residue in the EZH2SETdomain (EZH2F667I) abrogated itsmeth-
yltransferase activity and its ability to restore MHC-I repression
(Figure 2G). Interestingly, we noted that expression of the EZH2
F667Imutant inEZH2KOcells exerted a dominant negative effect,
further increasingMHC-I levels and implying thepresenceof resid-
ual PRC2activity in the absenceofEZH2.Consistentwith this, loss
of EEDmore potently inducedMHC-I than loss of EZH2, account-
ing for the lesser enrichment of sgRNAs targetingEZH2 compared
with those targetingEED in theCRISPRscreen (Figure1C). It iswell
established that the EZH2 paralog, EZH1, can also associate with
EED and SUZ12 to form functional PRC2 complexes. Although
EZH1-containingPRC2complexes have lessefficient lysinemeth-
yltransferase activity than EZH2-containing complexes, they may
compensate for the lossofEZH2 inspecificcellular contexts (Was-
sef and Margueron, 2017). Deletion of EZH1 in an EZH2 null clone
inducedadditionalMHC-Iupregulation, identifyinga role forEZH1-
mediated PRC2 activity in maintaining MHC-I repression in the
absence of EZH2 (Figure 2H). While most currently available
SAM-competitive and allosteric PRC2 inhibitors selectively target
EZH2with lesser potency for inhibition of EZH1 activity (Lee et al.,
2018), our data suggest that inhibitors that effectively target both
EZH2 and EZH1 catalytic activity may more effectively induce
MHC-I expression in MHC-I low cancers.
Disruption of PRC2 Function Induces Expression of
Multiple Components of the MHC-I APP Independently
of STAT1 Signaling
MHC-I antigen processing is orchestrated by a multistep
pathway that involves the coordinated regulation of multiple(D) Immunoblot in EED KO K-562 cells transduced with lentiviral vectors encodin
(E and F) Flow cytometry (E) and immunoblot and qRT-PCR (F) in K-562 cells tra
(G) Immunoblot in EZH2 KO K-562 cells transduced with lentiviral vectors encod
(H) Cell surface MHC-I in EZH2 KO K-562 cells transduced with either control sg
(I) qRT-PCR analysis in K-562 cells incubated with 3 mM EPZ-011989 for the i
representative experiment.
(J) qRT-PCR in K-562 Cas9 cells expressing control or STAT1 sgRNA, 7 days fo
For (F), (H), and (J), points indicate mean fold change in expression from individua
Figure S2.components. Across a range of tumor types we find that PRC2
silences critical genes essential for MHC-I antigen processing,
leading to upregulation of multiple MHC-I APP genes following
PRC2 inhibition, including those encoding anMHC-I transactiva-
tor (NLRC5), immunoproteasome components (PSMB8 and
PSMB9), peptide transporters associated with antigen process-
ing (TAP1 and TAP2), and MHC-I heavy chains (HLA-B and
HLA-C) (Figures 2I and S2D). Recent studies have shown that
inhibition of other epigenetic repressors such as DNA methyl-
transferases (DNMTs) and KDM1A (LSD1) augment MHC-I
expression in cancer cells via derepression of endogenous retro-
viruses, which activates type I IFN signaling (Chiappinelli et al.,
2015; Roulois et al., 2015; Sheng et al., 2018). STAT1 is an
essential mediator of the transcriptional response to types I
and II IFNs (Durbin et al., 1996) and, as expected, disruption of
STAT1 abolished IFN-g-induced MHC-I upregulation (Fig-
ure S2E). However, in contrast to the findings with KDM1A and
DNMT inhibitors (Sheng et al., 2018; Chiappinelli et al., 2015;
Roulois et al., 2015), initiation and maintenance of MHC-I tran-
scription following disruption of PRC2 function was independent
of STAT1, suggesting that this was not solely a consequence of
enhanced IFN signaling (Figures 2J and S2F). Consistent with
this, phosphorylated STAT1was not detected following EZH2 in-
hibition alone (Figure S2G). Collectively our findings imply a
conserved role for the PRC2 complex in the direct repression
of the multicomponent MHC-I APP and demonstrate that inhibi-
tion of PRC2 function is sufficient to restore cell surface MHC-I
expression.
PRC2 Restricts Transcriptional Induction of MHC-I in
Response to Cytokine Stimulation
While PRC2 inhibition alone increased MHC-I APP gene expres-
sion in multiple different MHC-I low tumor types (Figure 2C), in
the absence of additional cytokine stimulation the degree of in-
duction of cell surface MHC-I was variable in individual cancer
cell lines. It is well established that IFN-g-induced activation of
STAT1 and IRF1 augments MHC-I antigen presentation and
modulates the repertoire of peptides presented via induction of
the immunoproteasome. Consistent with the notion that PRC2
inhibition can potentiate the transcriptional response to IFN-g
(Zingg et al., 2017; Peng et al., 2015; Abou El et al., 2015), genetic
disruption of PRC2 dramatically augmented IFN-g-induced
MHC-I expression (Figure S3A). Expression of H3.3 K27M had
similar effects to PRC2 disruption suggesting that the enhanced
IFN-g-induced MHC-I expression is a direct consequence of
H3K27me3 loss (Figure 3A), rather than targeting of non-histone
substrates (Ardehali et al., 2017). These effects were conserved
in multiple MHC-I low cancers and pharmacological inhibition of
PRC2 using either SAM-competitive EZH2 inhibitors (EZH2i) org WT EED, EED W364A mutant, or GFP control (V).
nsduced with lentiviral vectors encoding H3.3 WT or K27M.
ing WT EZH2, EZH2 F667I, or GFP control (V).
RNA or two EZH1-specific sgRNAs.
ndicated times (days). Bars indicate the mean of technical triplicates from a
llowing transduction with sgRNA targeting EED.
l experiments and bars show mean fold change across experiments. See also
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Figure 3. PRC2 Restricts the Interferon-Induced Activation of MHC-I APP Genes in Multiple MHC-I Low Tumor Types
(A) Cell surface MHC-I in K-562 cells expressing H3.3 WT or H3.3 K27M treated with IFN-g 10 ng/mL for 24 h.
(B) Immunoblot in neuroblastoma (Kelly) cells treated with EPZ-011989 3 mM for 10 days ± IFN-g 10 ng/mL for 24 h.
(legend continued on next page)
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EED-226, an inhibitor that blocks H3K27me3 binding and allo-
steric activation of EZH2, markedly amplified IFN-g-induced
MHC-I upregulation (Figures 3B–3D, S3B, and S3C) (Qi et al.,
2017) and reduced the threshold concentration of IFN-g required
to induce MHC-I gene expression (Figures 3E and S3D).
Together these data demonstrate that PRC2 not only results in
baseline repression of MHC-I genes, but also restricts transcrip-
tional induction of these genes in response to cytokine
stimulation.
Core PRC2 members EED, SUZ12, and EZH1/EZH2 can form
various subcomplexes defined by their association with specific
accessory proteins. Depletion ofMTF2, whichwas identified as a
hit in the CRISPR screen and encodes a component of PRC2.1
complexes, also augmented IFN-g-induced MHC-I expression
(Figure 3F). MTF2 binds to both non-methylated CpG motifs
and H3K36me3 (Li et al., 2017), and has been proposed to
modulate PRC2 recruitment to specific loci in embryonic stem
cells (Holoch andMargueron, 2017). Consistent with an epistatic
role for MTF2 in maintaining MHC-I repression via modulation of
PRC2 function, loss of MTF2 had no additional effect on MHC-I
in EED KO cells (Figure S3E).
PRC2-Mediated Silencing ofMHC-I Drives Resistance to
T Cell Killing in SCLC
SCLC is a highly aggressive neuroendocrine carcinoma that is
strongly linked with smoking and has an extremely poor prog-
nosis. Notably, the rates of response to ICIs have been lower
than seen in other cancers with a similarly high mutational
burden (Alexandrov et al., 2013; Sabari et al., 2017). We found
that expression of EZH2 is negatively correlated with expression
of both MHC-I genes and markers of CD8+ T cells in primary
SCLC samples (Figure S4). To explore the effects of PRC2 inhi-
bition on T cell responses to SCLC, we established primary lung
tumor cell lines from a genetically engineered mouse model
(GEMM) driven by biallelic loss of Trp53 and Rb1. Biallelic inac-
tivation of TP53 and RB1 is a hallmark of human SCLC, and this
GEMM closely mimics human SCLC (Sutherland et al., 2011;
Meuwissen et al., 2003; George et al., 2015). Like human neuro-
endocrine tumors, mouse SCLC (mSCLC) lacked cell surface
MHC-I and exhibited low expression of multiple MHC-I APP
genes (Figures 4A and S5A), which were induced following ge-
netic disruption or pharmacological inhibition of PRC2 (Figures
4B, 4C, S5B, and S5C). As in K-562 cells, re-expression of wild
type (WT), but not catalytically inactive (F667I) EZH2 reinstated
MHC-I repression in Ezh2 KO mSCLC (Figure 4C). Like human
neuroendocrine tumor lines (Figure 3D), these early-passage
mSCLC lines showed variable MHC-I induction in response to
IFN-g stimulation (Figure 4A), while pretreating cells with PRC2
inhibitors markedly potentiated IFN-g-induced MHC-I upregula-
tion (Figures 4D, S5D, and S5E).
To explore the functional consequences of lowMHC-I expres-
sion in thesemSCLC cells, we pulsed cells with ovalbumin (OVA)
peptide (SIINFEKL), which binds to cell surface MHC-I (H-2Kb).(C and D) Cell surface MHC-I following incubation with IFN-g 10 ng/mL for 24 h
pretreated with EED-226 (D). Analysis after 10 days of inhibitor treatment.
(E) Cell surface MHC-I in EED KO or parental control K-562 cells incubated with
(F) Cell surface MHC-I in K-562 Cas9 cells expressing control sgRNA or two MT
See also Figure S3.Cells were washed to remove unbound peptide, before co-
culture with TCR transgenic OT-I T cells that specifically recog-
nize H-2Kb bound OVA peptide (Figure 4E). mSCLC cells were
highly resistant to antigen-specific T cell killing and failed to
induce T cell cytokine production (Figures 4F and 4G). Impor-
tantly, this resistance was dramatically reversed by pretreating
SCLC with both EZH2i and IFN-g to maximally induce MHC-I
expression before peptide pulsing, which led to effective T cell
activation (Figures 4F and 4G). These data clearly establish the
functional importance of MHC-I cell surface expression in this
model of SCLC.
We next investigated whether PRC2 inhibition restores intra-
cellular MHC-I antigen processing by engineering mSCLC cells
to express the full-length foreign protein chickenOVA (Figure 5A).
Intracellular processing of OVA generates the SIINFEKL peptide,
which is loaded onto MHC-I (H-2Kb) and specifically recognized
by the OT-I T cell receptor. Treatment of mSCLC-OVA cells with
EZH2i enabled IFN-g-inducible expression of OVA peptide
bound to MHC-I (SIINFEKL:Kb), which was not detected in
IFN-g-treated control cells (Figure 5B). In contrast to the peptide
pulsing assay (Figures 4E–4G), pretreatment with EZH2i alone
was sufficient to prime mSCLC-OVA cells to induce activation
of co-cultured OT-I T cells leading to pro-inflammatory cytokine
production (Figure 5C) and effective tumor cell killing over 96 h
(Figure 5D), establishing the functional importance of reversing
PRC2-mediated repression of the MHC-I APP. While pulsed
OVA peptide binds only to MHC-I already present at the cell sur-
face before adding T cells (Figures 4E–4G), co-culture of EZH2i
pretreated, but not control, OVA-expressing cells with OT-I
T cells induced MHC-I upregulation via a feedforward loop of
T cell activation (Figure 5E). Here, PRC2 inhibition alleviates tran-
scriptional repression of MHC-I leading initially to low level cell
surface expression, which primes SCLC to induce CD8+ T cell
activation and cytokine production. These cytokines further
enhance MHC-I antigen processing, resulting in efficient anti-
gen-specific T cell activation and killing.
PRC2 Facilitates Transmission of MHC-I-Silenced
Cancers to Non-histocompatible Recipients
To explore whether MHC-I downregulation evokes resistance to
T cell killing of SCLC cells in vivo, we subcutaneously trans-
planted C57Bl/6 (H-2b haplotype)-derived mSCLC cells into
BALB/c (H-2d haplotype) mice. Cells with foreign MHC are
expected to be eliminated by an allogeneic T cell response; how-
ever, these tumors were transmissible to BALB/c mice (Fig-
ure 6A) and lacked cell surface MHC-I with few tumor infiltrating
CD8+ T cells in either the allogeneic or syngeneic setting (Figures
S5F and S5G). The ability of SCLC cells to engraft and grow in
non-histocompatible recipients resembles that of rare transmis-
sible cancers such as the Tasmanian devil facial tumor (DFT),
which exemplifies immune evasion by cancer cells. Devils exhibit
modest diversity at MHC-I loci that should be sufficient to trigger
a T cell response; however, these tumors escape rejection by thein indicated cell lines pretreated with EPZ-011989 3 mM (C) and K-562 cells
the indicated concentrations of IFN-g for 24 h.
F2-specific sgRNAs incubated ± IFN-g 10 ng/mL for 24 h.
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Figure 4. PRC2-Mediated Silencing of MHC-I Antigen Presentation in a Mouse Model of SCLC Drives Resistance to T Cell Killing
(A) Cell surface MHC-I in mSCLC cell lines following incubation ± IFN-g 10 ng/mL for 24 h.
(B) qRT-PCR for MHC-I genes in mSCLC RP-116 cells treated with 3 mMEPZ-011989 or ethanol control for 10 days. Bars depict mean fold change in expression
from independent experiments and points indicate the mean of technical triplicates from individual experiments.
(C) qRT-PCR in Ezh2 KOmSCLCRP-116 transduced with a lentiviral vector encodingWT EZH2, EZH2 F667I, or GFP vector control. Bars showmean fold change
in expression from a representative experiment.
(D) Cell surface MHC-I in RP-116 cells treated with IFN-g for 24 h following pretreatment ± EED-226 3 mM for 10 days.
(E) Peptide pulsing assay. mSCLC RP-116 cells were pretreated as indicated with 3 mM EPZ-011989 or ethanol control for 10 days ± IFN-g 10 ng/mL for 24 h
before pulsing with OVA peptide.
(F) Percent remaining live target tumor cells following 24 h incubation with OT-I T cells at the indicated effector:target (E:T) ratios.
(G) Cytometric bead array (CBA) assay for T cell effector cytokines following 24 h co-culture with mSCLC cells pretreated as indicated. (F and G) Mean and SEM
from a representative experiment performed in triplicate. Each experiment was performed independently three times with consistent results.
See also Figures S4 and S5.devil immune system (Siddle, 2017). Interestingly, DFT1 tumors
lack cell surface MHC-I due to low expression of MHC-I APP
genes (Siddle et al., 2013). Like neuroblastoma, DFT is of neural
crest origin (Murchison et al., 2010) raising the possibility that392 Cancer Cell 36, 385–401, October 14, 2019similar mechanisms of MHC-I silencing may operate in these tu-
mors. Supporting an evolutionarily conserved role for PRC2 in
the repression of MHC-I antigen presentation, PRC2 inhibition






















at 24 hr (% of t0)
mSCLC-OVA 
cells remaining 
at 96 hr (% of t0)




















ETOH + T cells 24 hr






































Figure 5. Pharmacological Inhibition of EZH2 Overcomes Resistance to T Cell Killing in SCLC
(A) Schematic showingmSCLC-OVA co-culture assay. Stable expression of full-length OVA inmSCLC cells allows functional evaluation of the intracellular MHC-I
antigen-processing pathway. ProcessedOVA peptide bound to H2-Kb is presented at the tumor cell surface and recognized by co-cultured antigen-specific OT-I
T cells.
(B) Cell surface SIINFEKL:Kb (MHC-I bound OVA peptide) in OVA-expressing mSCLC RP-116 cells pretreated as indicated with 3 mM EPZ-011989 for 10 days ±
IFN-g 10 ng/mL for 24 h.
(C) CBA assay for T cell effector cytokines following 24 h co-culture with mSCLC-OVA cells pretreated as indicated.
(D) Percent remaining live mSCLC-OVA cells following incubation with OT-I T cells at the indicated effector:target (E:T) ratios.
(E) Cell surface MHC-I levels of mSCLC-OVA cells pretreated with EZH2 inhibitor ±24 h co-culture with OT-I T cells. (C and D) Mean and SEM from a repre-
sentative experiment performed in triplicate. Each experiment was performed three times with consistent results.(Figure 6B) and potentiated MHC-I induction following IFN-g
stimulation (Figure S6A). To evaluate the importance of PRC2-
mediated MHC-I repression for evasion of the potent allogeneic
CD8+ T cell-mediated anti-tumor response, we performed allo-
geneic transplants with Ezh2 KO mSCLC cells. Loss of EZH2
led to universal rejection of mSCLC tumors in BALB/c mice (Fig-
ures 6C, 6D), while the growth of EZH2-deficient mSCLC tumors
was not impaired either in vitro or following injection into immu-
nodeficient non-obese diabetic-severe combined immunodefi-
ciency IL2Rgnull mice that lack functional T, B, and natural killer
cells (Figures S6B and S6C). These findings confirm a critical
role for tumor-intrinsic PRC2 function in promoting immune
evasion in vivo.
To illustrate the clinical importance of our findings, we
evaluated MHC-I expression in a patient who presented with
an epidermal growth factor receptor (EGFR) mutant lung
adenocarcinoma that subsequently transformed to SCLC
following treatment with the EGFR inhibitor Erlotinib (Figure 6E).
Neuroendocrine transformation of both lung and prostateadenocarcinoma is increasingly been recognized as a mecha-
nism of escape from targeted therapies (Oser et al., 2015;
Aggarwal et al., 2018). In this patient, while being clonally
related to the adenocarcinoma and not showing any coding
mutations in MHC-I genes, the transformed SCLC exhibited
substantially reduced expression of components of the MHC-I
APP, including the MHC-I heavy chain, b2-microglobulin, and
the immunoproteasome component LMP7 (encoded by
PSMB8) (Figures 6E and S6D). Consistent with loss of MHC-I
antigen presentation, the tumor failed to respond to anti-PD-1
immunotherapy. Similar findings were noted in two additional
patients with neuroendocrine transformation of EGFR mutant
lung adenocarcinoma following treatment with EGFR inhibitors,
both of whom showed reduced MHC-I staining in the trans-
formed SCLC (Figure S6D). Together these data provide an
example of how neuroendocrine transformation, arising as a
mechanism of resistance to targeted therapies, may simulta-
neously confer immune privilege to a tumor through loss of
MHC-I antigen presentation.Cancer Cell 36, 385–401, October 14, 2019 393
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Figure 6. Silencing ofMHC-I Antigen Processing Is a Conserved Function of PRC2 that Facilitates Immune Evasion in Transmissible Cancers
(A) mSCLC RP-116 tumor growth following subcutaneous transplant into syngeneic C57BL/6 mice (100,000 cells) or allogeneic BALB/c mice (500,000 cells).
Endpoint at a tumor volume of 500 mm3.
(B) qRT-PCR analysis of MHC-I gene expression in DFT1 cells C5065 following treatment with 3 mM EED-226 for 10 days. Bars depict mean fold change in
expression from independent experiments and points indicate the mean of technical triplicates from individual experiments. SAHAI-1 encodes Tasmanian devil
MHC-I.
(C and D) Tumor growth in (C) and survival of (D) BALB/c mice subcutaneously injected with 106 Ezh2 KO or parental mSCLC RP-116 cells. Endpoint at a tumor
volume of 500 mm3. Six mice per group. p value calculated using Mantel-Cox test.
(E) Progression biopsy (left) and postmortem histology (right) in patient 1. Immunohistochemistry for neuroendocrine markers (synaptophysin and NCAM) and
MHC-I APP components (MHC-I, b2m, and LMP7). Area between the red lines in biopsy contains SCLC.
See also Figures S4 and S6.
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H3K27me3 Modification of MHC-I Genes
AlthoughPRC2complex components are ubiquitously expressed,
the genes repressed by PRC2 are highly cell-type specific (Comet
et al., 2016;Wassef andMargueron, 2017), highlighting the impor-
tance of understanding the molecular basis of PRC2 function in
different cellular contexts. Our observations that PRC2 inhibition
potentiates IFN-g-induced MHC-I expression prompted us to
couple H3K27me3 chromatin immunoprecipitation sequencing
with RNA sequencing (RNA-seq) analyses following genetic or
pharmacological inhibition of PRC2 in the presence and absence
of IFN-g. Theseexperimentswereconducted inhumanandmouse
cells to gain further insights into the conserved specificity of PRC2
function in cancerswith lowMHC-I.WhilemostH3K27me3-modi-
fied PRC2-regulated geneswere unaffected by exposure to IFN-g
(cluster3;Figures7AandS7A), inbothcell typeswe identifiedclus-
ters of genes that showed an augmented response to IFN-g
following disruption of PRC2 (clusters 1 and 2; Figures 7A and
S7A). Consistent with the known lineage-specific function of
PRC2, the defined set of PRC2-regulated IFN responsive genes
in each cell type were largely distinct, with the notable exception
of MHC-I APP genes (Figure S7B; Table S2). While PRC2 can
both directly and indirectly modulate cytokine signaling (Zingg
et al., 2017; AbouEl et al., 2015; Canadas et al., 2018), our findings
suggest thatH3K27me3modification ofMHC-I APPgenes plays a
critical role in maintaining MHC-I repression in cancer cells. Sup-
porting this, deletion of EED results in loss of H3K27me3 at
MHC-I APP gene promoter regions and MHC-I derepression,
which can be reinstatedbyWTEEDbut not anEEDmutant that re-
storesEZH2 levelsbuthas impairedbinding toH3K27me3 (Figures
7B and 2D).
Conserved Bivalent H3K4me3 and H3K27me3
Modification of MHC-I Genes in Multipotent Stem Cells
and Cancer Cells
Critical genes that are poised for expression in a tissue-specific
context are often concurrently marked by activating H3K4me3
and repressiveH3K27me3 histonemodifications, whichmaintain
genes in a silent but ‘‘poised’’ state to allow either rapid transcrip-
tional activation or progression to stable silencing (Bernstein
et al., 2006; Voigt et al., 2013). Given the evidence that MHC-I
expression is regulated during development and tissue-specific
differentiation, we explored whether silenced MHC-I genes are
marked by bivalent histone modifications. H3K27me3-modified
genes that were derepressed following PRC2 disruption had
higher average H3K4me3 levels at their promoters compared
with other H3K27me3-modified genes for which expression did
not significantly increase (Figure S7C; clusters 1–3 compared
with other H3K27me3-modified genes). Indeed, a substantial
proportion of the H3K27me3-modified genes responding to
PRC2 inhibition and IFN-g, including MHC-I APP genes, also
possessed H3K4me3 at their promoters (Figures 7C, S7D, and
S7E). The presence of bivalent H3K4me3 and H3K27me3 modi-
fications at MHC-I APP gene promoters was observed in a range
of humanMHC-I-deficient cancers aswell asmouse and Tasma-
nian devil tumors (Figures 7C and S7E). This conservation across
different tumor types and species implied that bivalency could
represent a physiological mechanism of MHC-I regulation.
Both neuroblastoma and DFT1 arise from cells of the embryonic
neural crest and share phenotypic features with SCLC and MCC(Murchison et al., 2010). Examination of MHC-I genes in neural
crest cells revealed that these genes contain bivalent chromatin
at their promoters and are transcriptionally repressed (Figures 7C
and S7E) (Minoux et al., 2017). Similarly, while MHC-I genes are
active in adult somatic tissues, we found that pluripotent tissues
such as embryonic stem cells exhibit bivalency at MHC-I gene
promoters, which is maintained during differentiation into neural
progenitors but is resolved during mesenchymal differentiation
(Figures 7D and 7E).
Disruption of PRC2Leads toDerepression of NLRC5 and
Enhanced IRF1 Binding at MHC-I Gene cis-Regulatory
Regions
A number of transcription factors are known to bind MHC-I gene
promoters and contribute to MHC-I expression (Rene et al.,
2016). Among these, IRF-1, nuclear factor kB (NF-kB), and
NLRC5 are key factors required for the transcriptional induction
of MHC-I genes in response to cytokine stimulation (Kobayashi
and van den Elsen, 2012). Interestingly, NLRC5 was repressed
by H3K27me3 in MHC-I low cancers and induced following
PRC2 disruption (Figure 8A).NLRC5 is an IFN-inducible gene en-
coding a transactivator that selectively binds MHC-I APP gene
promoters in association with a multisubunit complex termed
theMHC enhanceosome and plays a pivotal role in the regulation
of MHC-I expression (Figure 8B) (Kobayashi and van den Elsen,
2012). To identify the transcription factors driving MHC-I expres-
sion following loss of PRC2, we used targetedCRISPR-mediated
gene disruption in EED/EZH2 KO cells. While IFN-g-induced up-
regulation ofMHC-I is largely dependent onRFX5/NLRC5enhan-
ceosome function (Figure 8C), deletion of either NLRC5 or RFX5
only partially attenuatedMHC-I upregulation followingEEDKOor
EZH2 inhibition, suggesting that MHC-I induction following loss
of PRC2 is not driven throughNLRC5derepressionalone (Figures
8DandS8A).Wealsoobservedapartial requirement for IRF1, but
not the NF-kB transcriptional activator p65 (RelA), for MHC-I up-
regulation following EEDKO (Figures 8D, S8B, and S8C). Consis-
tent with a role for IRF1 in driving MHC-I expression following
PRC2 loss, IRF1 binding at MHC-I gene promoters increased
following PRC2 inhibition (Figures 8E and S8D). Genome-wide,
72 of 104 genes showing increased IRF1 occupancy following
PRC2 inhibition were modified by H3K27me3, implying that
PRC2 restricts IRF1 binding at these genes (Figure S8E). Notably,
although IFN-g stimulation leads to a greater transcriptional in-
duction of IRF1 and NLRC5 than EED KO alone, the relative
expression of HLA-B is similar in the two contexts (Figure 8F).
Together these findings are consistent with additional restriction
of HLA-B expression in the presence of an intact PRC2 complex
and suggest that loss of PRC2 activity and the consequent
decrease in H3K27me3 at the MHC-I APP genes is the initiating
process for gene expression. The loss of H3K27me3 provides a
permissive chromatin environment that alleviates the constraints
on cytokine stimulation and enables the subsequent binding of
transcription factors that further potentiate the expression of
MHC-I genes.
DISCUSSION
While cancers have previously been shown to corrupt the reso-
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genes to impair differentiation pathways and promote survival,
here we show how PRC2 function can be co-opted to maintain
bivalency at a subset of genes to evade immune surveillance.
The cell of origin appears to be central to this process and
PRC2-mediated silencing of MHC-I in both embryonic and tis-
sue-specific stem cell subsets likely evolved to protect these
cells from inflammation-related pathology (Agudo et al., 2018).
However, cancers that arise from these lineages can exploit
the activity of PRC2 to silence MHC-I antigen presentation and
gain immune privilege. Importantly, genetic disruption or phar-
macological inhibition of PRC2 restores tumor MHC-I antigen
presentation, allowing effective targeting by CD8+ T cells.
Our findings demonstrate a critical role for the PRC2 complex
in maintaining the coordinated silencing of critical components
of the MHC-I APP, including the immunoproteasome and TAP
peptide transporter as well as the MHC-I heavy chain genes. In
addition to direct modification of MHC-I APP genes, PRC2
also targetsNLRC5, derepression of which contributes to driving
MHC-I gene expression following PRC2 inhibition. It is well
recognized that only a proportion of PRC2 occupied and
H3K27me3 marked genes become transcriptionally active
following disruption of PRC2 function and loss of H3K27me3.
The transcriptional induction of PRC2 target genes following
PRC2 inhibition is largely determined by transcription factor
expression and therefore is cell type and context specific (Was-
sef and Margueron, 2017). We observed variability in the degree
to which PRC2 inhibition alone induced MHC-I gene expression
in individual neuroendocrine tumor lines, which may in part
reflect low basal expression of IRF1 and NF-kB components in
these malignancies (van ’t Veer et al., 1993). In contrast, PRC2
inhibition consistently augmented MHC-I gene expression
following IFN-g stimulation, which induces high levels of IRF1
and activated phosphorylated STAT1, highlighting the impor-
tance of PRC2 as a barrier to cytokine-mediated transcriptional
activation of MHC-I APP genes in these cancers. While our data
highlight a pivotal role for PRC2 inMHC-I APP regulation, our un-
biased CRISPR screen also identified other candidates. Future
work will provide insight into how these other chromatin regula-
tors cooperate with PRC2 and/or nuance its function to regulate
cell context dependent antigen presentation.
Here we have demonstrated a tumor-intrinsic function of
PRC2 in the regulation of antigen presentation within tumors
that arise from certain cell lineages. Our findings contribute to
an emerging body of literature that ascribes a key immune
modulatory function to PRC2. In addition to directly targetingFigure 7. An Evolutionarily Conserved Function of PRC2Maintains Biva
cific Progenitor Cells and in MHC-I Low Cancers
(A) RNA-seq heatmap displaying H3K27me3-modified genes upregulated by >1.5
control sgRNA. Cells were additionally pulsed ± IFN-g 10 ng/mL for 24 h. Genes w
Kmeans of 3. Red indicates higher expression and blue indicates lower expressio
(B) H3K27me3 chromatin immunoprecipitation (ChIP) qPCR at HLA-B and NLRC5
EED W364A. Fold enrichment was calculated relative to the signal at the GAPDH
(C) Bivalent H3K27me3 and H3K4me3 modification of MHC-I gene promoters in
sequencing (ChIP-seq) in K-562 and Tasmanian devil cells was performed in-hous
GEO: GSE80151 (Zeid et al., 2018), and NT2-D1 from GEO: GSE31755 (ENCOD
(D and E) Chromatin state discovery tracks in selected human embryonic stem
ChromHMM software integrating H3K27me3, H3K4me3, H3K27ac, and H3K36
(Kundaje et al., 2015). Generated chromatin annotation states for the TSS (tss) a
See also Figure S7 and Table S2.MHC-I APP genes, EZH2 inhibition can enhance tumor immuno-
genicity through derepression of endogenous retroviruses,
enhanced IFN signaling, and increased production of pro-inflam-
matory chemokines CXCL9 and CXCL10 (Canadas et al., 2018;
Peng et al., 2015; Zingg et al., 2017; Wee et al., 2014). EZH2
also plays a pivotal role in modulating immune cell differentiation
(Karantanos et al., 2016), and targeted EZH2 disruption in
regulatory T cells has been shown to enhance anti-tumor im-
mune responses in mouse tumor models (Wang et al., 2018;
Goswami et al., 2018). In conjunction with these studies, our
demonstration that tumor-intrinsic disruption of PRC2 leads to
re-establishment of effective T cell-mediated anti-tumor immu-
nity in MHC-I-deficient cancers provides a rationale for
combining inhibitors of the PRC2 complex with immunotherapy
to treat these aggressive malignancies.
MHC-I-deficient tumors such as neuroblastoma and SCLC are
characterized by highly aggressive growth with early and wide-
spread metastasis, features which epitomize failure to elicit an
effective anti-tumor adaptive immune response. Importantly,
SCLC and MCC possess potential foreign antigens, either neo-
antigens because of a high mutational burden or Merkel cell pol-
yomavirus antigens. Silencing of MHC-I genes, likely coupled to
the neuroendocrine differentiation program characteristic of
these cancers, could therefore facilitate evasion of immune sur-
veillance from an early stage in their development. Melanomas
are immunogenic tumors that typically express high levels of
MHC-I; however, melanocytes originate from the neural crest,
and selective transcriptional downregulation of HLA-B has
been reported in melanoma cell lines (Marincola et al., 1994),
while melanoma dedifferentiation with expression of neural crest
markers has been linked to acquired immunotherapy resistance
(Landsberg et al., 2012; Mehta et al., 2018). Dedifferentiation or
transformation of tumors is an emerging theme in the context
of targeted therapy. As illustrated by our clinical cases, neuroen-
docrine transformation may provide an additional advantage to
the tumor by coupling therapeutic resistance with suppression
of antigen presentation. The molecular insights described here
provide the rationale for future therapeutic strategies that incor-
porate PRC2 inhibition to negate this immune privilege. In
summary, our findings provide a detailed molecular understand-
ing of how MHC-I-deficient cancers co-opt an evolutionarily
conserved, lineage-specific function of an epigenetic complex
to evade immune surveillance. They also raise the prospect
that resistance to cancer immunotherapies may occur not only
through genomic mutations that inactivate the MHC-I APP butlency at MHC-I Gene Promoters in Embryonic Stem and Tissue-Spe-
log2FC in K-562 7 days following transduction with EED sgRNA compared with
ere clustered using Euclidean clustering, and clusters were separated using a
n.
promoters in EED KO K-562 transduced with control GFP vector, WT EED, or
promoter (negative control). Bars show the mean of three technical replicates.
human and Tasmanian devil cancer cells and mouse neural crest cells. ChIP
e. Neural crest data are fromGEO: GSE89435 (Minoux et al., 2017), BE2-C from
E Project Consortium, 2012). y axes indicate reads per million (rpm).
and progenitor cells (D) and normal adult human tissues (E) generated using
me3 ChIP-seq data from NIH Roadmap Epigenomics Mapping Consortium
nd gene body (gb) of the indicated genes are shown.





Figure 8. Disruption of PRC2 Leads to Derepression of NLRC5 and Enhanced IRF1 Binding at MHC-I Gene cis-Regulatory Regions
(A) RNA-seq and H3K27me3 ChIP-seq data in K-562 cells displaying reported transcriptional regulators of MHC-I expression. RNA-seq heatmap shows log2FC
gene expression of K-562 cells expressing an EED sgRNA compared with control sgRNA at 7 and 10 days post-transduction. The H3K27me3 ChIP-seq heatmap
shows the number of reads at 2 kb upstream of tss, genebody and 2 kb downstream of tes (transcription end site) of each gene.
(B) A schematic presentation of cis-regulatory elements in the HLA-B promoter. NLRC5 forms an enhanceosome with the regulatory factor X (RFX) complex,
comprising RFX5, RFXANK (RFX-associated ankyrin-containing protein), and RFXAP (RFX-associated protein). CREB (cAMP-responsive-element-binding
protein 1); NFY (nuclear transcription factor Y); ISRE (IFN-stimulated response element); USF1 (upstream stimulatory factor 1).
(C) Cell surface MHC-I in K-562 Cas9 cells expressing control, NLRC5-, or RFX5-specific sgRNA following incubation with IFN-g 10 ng/mL for 24 h.
(legend continued on next page)
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also through non-genomic mechanisms that exploit the activity
of repressive chromatin complexes such as PRC2.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Lung Cancer Samples
Patient 1 and patient 3 participated in the CASCADE (CAncer tissue Collection After DEath) rapid autopsy program, which was
approved by the Peter MacCallum Cancer Centre Ethics Committee (HREC 11/102). Patient 2 participated in the Thoracic Malig-
nancies Prospective Cohort Study, approved by the PeterMacCallumCancer Centre Ethics Committee (HREC 11/88). Informed con-
sent was obtained from all patients.
Clinical Details
Patient 2 was a 63 year old female non-smoker, who was diagnosed with a primary lung adenocarcinoma with an EGFR exon 19
deletion. She underwent a right upper lobectomy to remove the tumor. 3 years later she was diagnosed with metastatic disease,
and biopsy confirmed lung adenocarcinoma, which retained the original EGFR mutation (adenocarcinoma samples in Figure S6D).
She was initially treated with the EGFR inhibitor Erlotinib, followed by Osimertinib after developing an EGFR T790M mutation that
confers Erlotinib resistance. After 2 years of EGFR inhibitor treatment she developed progressive disease and biopsy showed small
cell carcinoma, which remained positive for the EGFR exon 19 deletion (SCLC samples in Figure 6D). She received chemotherapy for
the small cell carcinoma but had ongoing progressive disease and died 7 months later.
Patient 3 was a 59 year old female non-smoker, who was diagnosed with metastatic (stage 4) EGFRmutant lung adenocarcinoma.
She was treated with the EGFR inhibitor Gefitinib. 16 months later she developed progressive disease and was treated with chemo-
therapy, followed by Erlotinib and then Afatinib as she failed to respond. She had ongoing progressive disease and repeat biopsy
showed small cell transformation (SCLC samples in Figure 6D). She received chemotherapy followed by nivolumab, however failed
to respond to this and died 3 months later.
Cell Lines
Human neuroblastoma cell lines Kelly and IMR-32 were a gift from Paul Ekert (Murdoch Children’s Research Institute). Human SCLC
lines NCI-H82 andNCI-H146were a gift from Jonathan Yewdell (National Institute of Allergy and Infectious Diseases, Bethesda). Tas-
manian Devil Facial Tumor 1 (DFT1) C5065 cells were a gift from Andrew Flies (University of Tasmania) and were established with
approval from Tasmanian Government Department of Primary Industries, Parks, Water and the Environment (DPIPWE). HEK-
293ET cells were a gift from Dr. Felix Randow (MRC-LMB, Cambridge, UK). K-562 and NCI-H69 cells were from ATCC. HumanMer-
kel Cell Carcinoma lineMCC-002was derived from a patient withMerkel cell polyoma virus positiveMerkel Cell Carcinoma. Informede3 Cancer Cell 36, 385–401.e1–e8, October 14, 2019
patient consent and Institutional Review Board approval were obtained according to the guidelines of the Australian National Health
and Medical Research Council approved by the Peter MacCallum Cancer Centre Human Research Ethics Committee (Protocol: 14-
113). The tumor was mechanically disaggregated to a single cell suspension and propagated in RPMI-1640, supplemented with
2 mM Glutamax, 100 IU/mL Penicillin, 100 mg/mL Streptomycin and 5% heat-inactivated fetal calf serum (HI-FCS). Mouse SCLC
cell lines RP-48, RP-116 and RP-186 were established from primary lung tumors in a genetically engineered model driven by con-
ditional bi-allelic inactivation of the tumor suppressor genes Trp53 and Rb1 (p53Rb) (Sutherland et al., 2011; Meuwissen et al., 2003).
These mice carry conditional alleles for Rb1 (floxed exon 19) and Trp53 (floxed exons 2–10). Intra-nasal delivery of an adenoviral to
CMV-Cre-recombinase vector to p53Rbmice results in somatic inactivation of Trp53 andRb1 in pulmonary cells and the subsequent
development of high-grade neuroendocrine tumors, which have been shown to be morphologically and phenotypically similar to
human SCLC, with a median latency of 200-300 days (Sutherland et al., 2011; Meuwissen et al., 2003). Tumors were mechanically
disaggregated and cultured in DMEM/F12 (Gibco) with 15 mM HEPES, supplemented with 2 mM Glutamax (Invitrogen), 100 IU/mL
Penicillin, 100 mg/mL Streptomycin, 4 mg/mL Hydrocortisone (Sigma-Aldrich), 5 ng/mL EGF (Invitrogen), 5 mL of Insulin-Transferrin-
Selenium solution (Life Technologies) and 10% HI-FCS. Tumor cells grew as spherical aggregates in suspension. Other human and
DFT1 cell lines were cultured in RPMI-1640 or DMEM (HEK-293ET), supplemented with 2 mM Glutamax, 100 IU/mL Penicillin,
100 mg/mL Streptomycin and 10% HI-FCS. CD8 T cells isolated from mice were cultured in complete RPMI-1640 media (10% HI-
FBS, 100 IU/mL Penicillin, 100 mg/mL Streptomycin, 1 mM sodium pyruvate, 2 mM Glutamax and 0.05 nM 2-mercaptoethanol.
Drosophila S2 cells (ATCC catalog number CRL-1963; Biovest part number OO.763/OO.627) were cultured in Schneider’s
Drosophilamedia (Life Technologies) supplemented with 10% FBS. All cell lines were cultured in 5% CO2 at 37
Cwith the exception
of C5065 cells, which were cultured in 5% CO2 at 35
C and Drosophila S2, which were cultured at room temperature.
Cell lines were authenticated by STR profiling through the Australian Genome Research Facility (Melbourne, Victoria). Cell lines
were regularly tested and verified to be mycoplasma-negative by PCR analysis through the Victorian Infectious Diseases Reference
Laboratory (Melbourne, Victoria).
Animal Experiments
For in vivo experiments, mSCLC RP-116 cells or RP-116 Ezh2 KO clones, were resuspended in 50:50 PBS:Matrigel (Growth factor
reduced) and injected subcutaneously in a 100 mL volume into female C57BL/6 or Balb/c mice, purchased from the Walter and Eliza
Hall Institute (Melbourne, Australia). Experiments in Figures 6C and 6Dwere performed using Ezh2 KO clone 1. The survival endpoint
was when tumors reached a size of 500 mm3. Mice were used between 6 and 12 weeks of age. All animal studies were approved in
advance by the Peter MacCallum Animal Ethics and Experimentation Committee and theWalter and Eliza Hall Institute Animal Ethics
Committee and all ethical obligations were met.
METHOD DETAILS
Chemicals
EPZ-011989, EED-226 and GSK-503 were purchased from Selleck Chemicals. For each inhibitor, titration experiments were per-
formed to determine the maximally effective, tolerated dose in each cell line. Doses used and duration of treatment are indicated
in the figure legends. Cells were typically treated for 7-12 days prior to analysis. Drugswere refreshed 3 times per week. For interferon
induction of MHC-I expression, human cells were treated with recombinant human interferon gamma (Sigma-Aldrich) and mouse
cells with recombinant mouse interferon gamma (Abcam) at a dose of 10ng/mL for 24 hours (unless specified otherwise in figure
legend) prior to analysis. Recombinant Tasmanian devil interferon gamma was generated and purified as previously described (Flies
et al., 2016).
Plasmids
pCDH-EF1-Puro lentiviral vectors encoding HA-FLAG-tagged wildtype H3.3 and H3.3 K27M were a kind gift from Peter Lewis (Uni-
versity ofWisconsin) (Lewis et al., 2013). To generate lentiviral EED and EZH2 expression plasmids, wild-type EEDwas PCR amplified
from pCMV HA EED WT (Addgene 24231, a gift from Kristian Helin) (Bracken et al., 2003) and subcloned into pHRSIN-PSFFV-eGFP-
PPGK-Puro via BamHI and XhoI, replacing the GFP. Mouse EZH2 and EZH2 F667I were subcloned into pHRSIN-PSFFV-eGFP-
PPGK-Puro via BamHI and XhoI following PCR amplification from MSCVhygro-F-Ezh2 wild-type or F667I (Addgene 24926 and
24927, a gift from Kai Ge) (Wang et al., 2010). For all constructs the N-terminal tag (HA or FLAG) was removed during cloning.
The EED W364A mutant was generated by site-directed mutagenesis of wildtype EED that had been subcloned into pcDNA3.
Following sequence verification, EED W364A was subcloned into pHRSIN-PSFFV-eGFP-PPGK-Puro. All plasmids were verified by
Sanger sequencing analysis through the Australian Genome Research Facility (Melbourne, Victoria). An ovalbumin (OVA) expressing
retroviral vector was generated by PCR amplification of full-length chicken OVA from pcDNA3-OVA (Addgene 64599, a gift from San-
dra Diebold & Martin Zenke) (Diebold et al., 2001) and cloned into MSCV-IRES-mCherry via EcoRI and NotI sites.
CRISPR sgRNA Library
The screen was performed using the Bassik Human CRISPR KO Library (a gift from Michael Bassik, Addgene 101296-101934). This
10-sgRNA-per-gene CRISPR/Cas9 deletion library was designed to target all 20,500 protein-coding human genes. The library
contains two distinct classes of negative control gRNAs: non-targeting control sgRNA with no binding sites in the genome andCancer Cell 36, 385–401.e1–e8, October 14, 2019 e4
safe-targeting sgRNA targeting genomic locations with no annotated function. Further details are described in Morgens DW et al
(Morgens et al., 2017). Library sgRNAs are expressed in the pMCB320 lentiviral sgRNA expression vector, which encodes puromycin
and mCherry selection markers.
CRISPR Screen
K-562 cells were transducedwith a lentiviral vector encoding Cas9 and selectedwith blasticidin. For the screen, 108 K-562 Cas9 cells
were infected with the pooled lentiviral genome-wide sgRNA library at a multiplicity of infection of 0.3. The percent of cells infected
was determined by flow-cytometry based evaluation of mCherry positive (sgRNA expressing) cells 72 hr following transduction. In-
fected cells were selected with 1 mg/mL puromycin for 72 hr, commencing 48 hr after transduction. Rare MHC-I positive cells were
enriched by three rounds of FACS sorting at day 7, day 15 and day 30 following transduction with the sgRNA library. For the first and
second sorts, cells were stained with APC-conjugated anti-human HLA-A,B,C antibody (W6/32, BioLegend) for 15 minutes on ice
and washed with PBS prior to sorting for mCherry positive (sgRNA expressing) MHC-I positive cells on a BD Influx cell sorter. For
the third sort, two parallel sorts were performed using either a pan-HLA-A, B, C-specific antibody or using anHLA-B specific antibody
(REA143, Miltenyi Biotec). Genomic DNA was extracted (Puregene Core Kit A, Qiagen) from both the sorted cells and an unselected
pool of mutagenized cells grown for the same amount of time. sgRNA sequences were amplified by two rounds of PCR, with the
second round primers containing adaptors for Illumina sequencing. Samples were sequenced with single-end 50 bp reads on an
Illumina HiSeq. The sequence reads were trimmed to remove the constant portion of the sgRNA sequences with fastx clipper
(http://hannonlab.cshl.edu/fastx_toolkit/), then mapped to the reference sgRNA library with bowtie2. After filtering to remove
multi-aligning reads, the read counts were computed for each sgRNA. The RSA algorithm (Konig et al., 2007) was used to rank
the genes for which targeting sgRNA were significantly enriched in the sorted populations compared to the control unsorted popu-
lations grown in parallel.
CRISPR/Cas9-Mediated Gene Disruption and Generation of Knockout Clones
Single guide RNA (sgRNA) oligonucleotides (Sigma-Aldrich) were cloned into lentiviral expression vector pKLV-
U6gRNA(BbsI)-PGKpuro2ABFP as described (Addgene 50946, a gift from Kosuke Yusa). For CRISPR/Cas9mediated gene disruption,
cells were first transduced with the Cas9 expression vector pHRSIN-PSFFV-Cas9-PPGK-Blasticidin (Burr et al., 2017) or
FUCas9Cherry (a gift from Marco Herold, Addgene 70182), and selected with blasticidin or sorted for mCherry expression
respectively. To generate polyclonal populations with targeted gene disruption, cells were subsequently transduced with pKLV-
gRNA-PGKpuro2ABFP encoding either gene specific sgRNAs or with a control sgRNA targeting a ‘safe’ genomic location with no an-
notated function (Morgens et al., 2017). Efficient functional CRISPR/Cas9mediated gene disruption of EED and EZH2was confirmed
by immunoblot for H3K27me3 and of IRF1, STAT1 and RFX5 was confirmed by loss of IFN-g-induced MHC-I upregulation. To
generate EED and EZH2 KO clones used in complementation experiments, sgRNAs targeting either EED or EZH2 were transiently
expressed using lentiviral infection coupled with treatment with the integrase inhibitor raltegravir (Selleck Chemicals), which effec-
tively inhibits lentiviral integration. This method allows highly efficient CRISPR/Cas9-mediated gene disruption following transient
sgRNA expression in non-adherent cells. Cas9-expressing K-562 or mSCLC cells were transduced with pKLV-gRNA-PGKpuro2ABFP
expressing EED or EZH2 specific sgRNA. 2 nM raltegravir was added during transduction and continued for 10 days. Effective inhi-
bition of integration was confirmed by gradual loss of BFP expression from day 3 following infection. Control cells were transduced
with a control sgRNA targeting a ‘safe’ genomic location and treated under the same conditions. Cells were selected with puromycin
2 mg/mL for 24 hr, beginning 24 hr following transduction, and subsequently single cell sorted into 96-well plates using aBD FACSAria
Fusion flow cytometer. Clones were screened by immunoblot for H3K27me3 and EZH2 and FACS for cell surface MHC-I. Identified
EED/EZH2 KO clones were verified to be BFP negative and sensitive to puromycin to exclude integration of the lentiviral sgRNA vec-
tor. To generate Ezh2 KOmSCLC (RP-116) clones lacking Cas9 expression for in vivo experiments, Cas9 and the sgRNAs were both
transiently expressed as described above and single cell clones established. For complementation experiments, selected EED or
EZH2 KO K-562 or mSCLC RP-116 clones were infected with pHRSIN-PPGK-Puromycin encoding wildtype or mutant EED or
EZH2 and selected with puromycin.
Lentiviral Production and Transduction
Lentivirus was produced by triple transfection of HEK-293ET cells with a lentiviral transfer vector, and the packaging plasmids
psPAX2 and pMD.G at a 0.5:0.35:0.15 ratio. Transfection was performed using JetPEI reagent as recommended by the manufac-
turer. The viral supernatant was collected 60 hr following transfection, filtered through a 0.45 mm filter, and added to target cells.
Flow Cytometry
Cells were washed in PBS and stained on ice for 20-30 min in PBS plus 2% FCS. After washing in PBS/2% FCS, samples were
either resuspended in PBS/2% FCS or fixed in 1% paraformaldehyde (PFA). Data were acquired on a BD LSR Fortessa or BD
FACSymphony and analysed in FlowJo.
Immunoblotting
Cells were lysed in 1%SDS in 100mM Tris-HCl pH 8.0 with Roche complete EDTA-free protease inhibitor at room temperature. DNA
was fragmented either by sonication or adding Benzonase (Sigma) 1:100. Lysates were heated to 70C in SDS sample buffer withe5 Cancer Cell 36, 385–401.e1–e8, October 14, 2019
50 mM DTT for 10 min, separated by SDS-PAGE, and transferred to PVDF membrane (Millipore). Membranes were blocked in 5%
milk in TBS + 0.1% Tween-20, probed with the indicated antibodies, and reactive bands visualised using West Pico (Thermo Fisher
Scientific).
Fluorescent Multiplex Immunohistochemistry
4 mm thick formalin-fixed paraffin-embedded sections of mSCLC tumors grown in BALB/c or C57BL/6 mice were baked at 60C for
30 minutes prior to being loaded onto the Leica BOND RX for automated fluorescent multiplex immunohistochemistry. The first heat
induced antigen retrieval was performed with EDTA pH 9. Tissue sections were incubated with a protein block supplied by the manu-
facturer within the Opal immunostaining kit (NEL811001KT, Perkin Elmer) for 10 min and then immersed in 3% hydrogen peroxide for
10 min. The first primary antibody, rabbit a-mouse NCAM (95153, Abcam), 1:400, was applied to tissue sections and incubated at
room temperature for 1 hour followed by a 10 minute incubation with an a-rabbit HRP-conjugated secondary antibody
(NEF812001EA, Perkin Elmer), 1:1000. This was followed by 10 min incubation with tyramide-conjugated fluorophore working solu-
tion, consisting of fluorophore diluted to 1:150 in the amplification diluent supplied by Perkin Elmer. This process was repeated for
each of the following antibodies (with the exception of the hydrogen peroxide block which was only performed once). Citrate buffer
pH 6 was used for the second heat induced antigen retrieval followed by incubation with monoclonal rabbit a-CD3 antibody (16669,
Abcam), 1:100. EDTA pH 9 was used for the final heat induced antigen retrieval followed by incubation with rabbit a-mouse CD8-
alpha antibody (209775, Abcam), 1:2000. DAPI was then applied to tissue sections for 3 minutes at room temperature.
Image acquisition of stained tissue sections was performed on the Vectra 3.0 Multispectral Imaging Platform (Perkin Elmer). Spec-
tral un-mixing of fluorophores was performed using the software, inForm (Perkin Elmer), whilst digital analysis of tissue sections was
performed using the software, HALO v2.2.1870 (Indica Labs, USA). The analysis algorithm developed for this study used the Highplex
FL v.2.0 module, specific for analysis of multiplex immunohistochemical stained tissue sections.
Isolation and In Vitro Activation of CD8+ T Cells
OT-I TCR Transgenic mice were purchased from the Walter and Eliza Hall Institute (Melbourne, Australia). Splenocytes were har-
vested from the spleen of OT-I mice and stimulated by incubation with 300 ng/mL of SIINFEKL (OVA peptide) (Sigma-Aldrich) for
24 hr to expand CD8+ OT-I T cells. After washing to remove the peptide, cells were cultured in media supplemented with IL-2 at
100 U/mL (Abcam) for an additional 2 days. T cells were subsequently isolated from the mononuclear layer using Ficoll separation
and cultured with IL-2 for an additional 3 days before use in co-culture assays. Successful enrichment of a CD8+ T cell population
was confirmed by flow cytometry staining for CD45, CD3 and CD8.
T-cell Cytotoxicity Assays
Peptide Pulsing Assay
mSCLC cells were pretreated as indicated with 3 mM EPZ-011989 or ethanol control for 10 days, and then incubated with or without
IFN-g 10 ng/mL. After thoroughwashing to remove the inhibitor and IFN-g, cells were pulsedwith 1 ng/mL of SIINFEKL (OVA peptide)
at 37C for 2 hours, which binds to cell surface MHC-I (H-2Kb). Cells were subsequently washed to remove unbound peptide and
then mixed at a 1:1 ratio with control mCherry positive untreated mSCLC cells (expressing an MSCV mCherry control vector). Cell
mixtures were individually plated in 96-well plates and T cells added at a range of different effector:target ratios. Assays were set
up in triplicate wells for each co-culture condition. After incubation at 37C for 24 hr, samples were analyzed by flow cytometry to
determine the percent killing of peptide-pulsed cells for each pretreatment condition. This was determined for each effector:target
ratio by comparing the relative percent of target (mCherry negative) tumor cells remaining in the wells that received T cells compared
to the wells that did not receive T cells. Tumor cells were identified as the viable (Fixable Violet negative), CD45 negative population.
As an additional control to evaluatewhether tumor cell killing wasMHC-I antigen-specific, assayswere set up as described above but
omitting the peptide pulsing step to determine whether tumor cell killing was dependent on the presence of the peptide specifically
recognized by the OT-I T-cell receptor.
OVA Peptide Processing and Presentation Assay
Ovalbumin (OVA) expressingmSCLC cells (mSCLC) were generated by infection with MSCV-OVA-mCherry. mSCLC-OVA cells were
pretreated as previously described with 3 mM EPZ-011989 or ethanol control for 10 days, and then incubated with or without
10 ng/mL IFN-g. After thorough washing to remove the inhibitor and IFN-g, pretreated mSCLC-OVA cells (mCherry positive) were
mixed with untreated parental mSCLC cells (mCherry negative) at a 1:1 ratio. Cell mixtures were analyzed by flow cytometry at base-
line to determine the percent of mSCLC-OVA (mCherry positive) cells. Cell mixtures were individually plated in 96-well plates and
T cells added at a range of different effector:target ratios. Assays were set up in triplicate wells for each co-culture condition. After
incubation at 37C for the indicated times, co-cultures were analyzed by flow cytometry as described above. The relative depletion of
mSCLC-OVA cells in the presence or absence of T cells was calculated by comparing the relative percent of mSCLC-OVA (mCherry
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Measurement of T-cell Cytokine Secretion
1x105mSCLC ormSCLC-OVA cells, pretreated as indicated in the figure legends, were co-cultured with 2 x 105OT-I T cells in 96-well
plates. Co-cultures were performed in triplicate for each condition. The cell culture media was collected after 24 hours of co-culture.
The levels of TNFa and IFN-g were measured with the BD cytometric bead array Mouse Th1/Th2 cytokine kit and analyzed by flow
cytometry.
qRT–PCR
mRNA was prepared with a Qiagen RNeasy kit, and cDNA synthesis was performed with a SuperScript VILO kit (Life Technologies),
per the manufacturers’ instructions. Quantitative PCR analysis was performed on an Applied Biosystems StepOnePlus System with
SYBR Green reagents. All samples were assayed in triplicate. Relative expression levels were determined with the DCt method and
normalized to GAPDH and/or ACTB.
RNA-Sequencing
RNA was extracted using the Qiagen RNeasy kit. RNA concentration was quantified using a Qubit Fluorometer (Thermo Fisher
Scientific). Libraries were prepared using QuantSeq 30 mRNA-seq Library Prep kit (Lexigen). Libraries were sequenced on the
NextSeq500 using 75 bp single end chemistry.
RNA-Sequencing Analysis
Bcl2fastq (Illumina) was used to perform sample demultiplexing and to convert BCL files generated from the sequencing instru-
ment into FastQ files. Reads were aligned to the human genome (G1k V37), or mouse genome (MM10) using HiSAT2 and reads
were assigned to genes using htseq-count. Differential expression was calculated using either limma, voom or DESeq2. Genes
with a false discovery rate corrected for multiple testing using the method of Benjamini and Hochberg below 0.05 and a
fold change greater than 1.5 were considered significantly differentially expressed. Heatmaps were generated in R using
pheatmap.
Chromatin Immunoprecipitation (ChIP)
Chromatin immunoprecipitation was performed as described previously (Gilan et al., 2016). Cells were cross-linked with 1%
formaldehyde for 15 min at room temperature, and cross-linking was stopped by the addition of 0.125 M glycine. Cells were
washed in ice cold PBS and either flash frozen and stored at -80C or directly lysed in 1% SDS, 10 mM EDTA, 50 mM Tris-
HCl, pH 8.0, and Roche complete EDTA-free protease inhibitor. For normalization of H3K27me3, H3K4me3 and H3K27ac
ChIP, Drosophila S2 cells cross-linked and lysed under the same conditions were mixed with the target cell lysates at a ratio
of 1:4 (Drosophila S2 cell number:target cell number). Lysates were sonicated in a Covaris ultrasonicator to achieve a mean
DNA fragment size of 500 bp. Samples were diluted 1:10 in modified RIPA buffer (1% Triton X-100, 0.1% deoxycholate,
90 mM NaCl, 10 mM Tris-HCl pH 8.0, and protease inhibitors) and incubated rotating with antibody for a minimum of 12 hr
at 4C. Antibodies used were rabbit anti-H3K27me3 (C37B11, Cell Signaling), rabbit anti-H3K27ac (ab4729, Abcam), rabbit
anti-H3K4me3 (ab8580, Abcam) and rabbit a-IRF-1 (D5E4, Cell Signaling), 8 to 10 mg per sample. Protein A Dynabeads (Life
Technologies) were added to bind the antibody and associated chromatin and samples incubated for 2 hr at 4C. After washing
twice with low salt buffer (0.1% SDS, 1% Triton X-100, 20 mM Tris-HCl pH8.0, 2 mM EDTA, 150 mM NaCl), once with high salt
buffer (0.1% SDS, 1% Triton X-100, 20 mM Tris-HCl pH 8.0, 2 mM EDTA, 500 mM NaCl) and once with TE (10 mM Tris [pH 8.0],
1 mM EDTA), samples were eluted from the beads for 30 min at 65C in elution buffer (1% SDS, 0.1 M NaHCO3). Eluates were
reverse cross-linked overnight by heating at 65C with RNase A and 0.2 M NaCl and then purified using the QIAquick PCR pu-
rification kit (Qiagen). DNA was analyzed by qPCR on an Applied Biosystems StepOnePlus System with SYBR Green reagents.
Sequencing libraries were prepared from eluted DNA using Rubicon ThruPLEX DNA-seq kit or NEB Next ChIP-seq library prep-
aration kit. Libraries were size selected between 200-700 bps and sequenced on the NextSeq500 using 75 bp single-end
chemistry.
ChIP-Sequencing Analysis
Bcl2fastq (Illumina) was used to perform sample demultiplexing and to convert BCL files generated from the sequencing instru-
ment into FastQ files. Reads were aligned to the human genome (GRCh37) or mouse genome (GRCm38), combined with fly
genome (BDGP5) or a modified Tasmanian devil genome (Devil_ref v7.0) with BWA-mem. The scaffold GL857536.1 encoding
the TAP2 gene was replaced with a BAC clone (accession FQ482140) encoding the whole TAP cluster of genes (Cheng Y
2012. BMC Genomics, Antigen-presenting genes and genomic copy number variations in Tasmanian devil MHC), in the Tasma-
nian devil genome. Peak calling was performed with MACS2 with default parameters, and deepTools was used for normaliza-
tion. Genome-browser images of ChIP–seq data was generated by converting files to TDF files with igvtools and viewing in IGV.
ChIP-seq coverage across selected genomic regions was calculated with BEDtools57. ChIP heatmap was created using data
generated by ngsplot, the transcriptional start site (tss) is 2kb upstream of the gene start site, genebody was separated into 5
even bins, and the transcriptional end site (tes) is the end of the gene plus 2kb downstream. Chromatin state analysis was per-
formed using ChromHMM with either bed or bam files with H3K27me3, H3K27ac, H3K4me3 and H3K36me3 ChIP-seq data for
each cell type, specifying a 9 state parameter. Active (tss) was assigned to high H3K27ac and H3K4me3 at 500 bp around the
tss, bivalent tss was assigned to high H3K27me3 and H3K4me3 at 500 bp around the tss. Strong transcription was assigned toe7 Cancer Cell 36, 385–401.e1–e8, October 14, 2019
high H3K36me3 signal, weak transcription was assigned to low H3K36me3 signal, repressed polycomb was assigned to high
H3K27me3 signal, and inactive genes was assigned to no signal along the genebody. The heatmap for the chromatin state was
generated in R.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was carried out using GraphPad Prism 8. Details of statistical analysis performed in Methods Details of STAR
Methods and in the figure legends. Data were reported as mean ± SEM or independent replicates shown as individual data points,
as indicated in the figure legends. Significance was defined as p < 0.05.
DATA AND CODE AVAILABILITY
Sequencing data has been deposited into the sequence read archive, hosted by the National Centre for Biotechnology Information.
The accession number for the sequencing data reported in this paper is NCBI sequence read archive: PRJNA527170. Unprocessed
data (immunoblot scans) are available at https://doi.org/10.17632/yf4vcxy469.1.Cancer Cell 36, 385–401.e1–e8, October 14, 2019 e8
